Trial
NCT03391765
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AbbVie
Collaborators
—
Condition
Progressive Supranuclear Palsy (PSP)
Intervention
ABBV-8E12
Why stopped
This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-03